Market Research Logo

Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2018

Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2018

Summary

Human Papillomavirus Protein E7 (E7) - Human Papilloma Virus (HPV) E7 protein belongs to a group of proteins called oncoproteins. It plays a role in viral genome replication by driving entry of quiescent cells into the cell cycle. E7 protein has both transforming and trans-activating activities. It induces the disassembly of the E2F1 transcription factor from RB1, with subsequent transcriptional activation of E2F1-regulated S-phase genes. Ii interferes with host histone deacetylation mediated by HDAC1 and HDAC2, leading to transcription activation. It plays an important role in the inhibition of both antiviral and antiproliferative functions of host interferon alpha.

Human Papillomavirus Protein E7 (E7) pipeline Target constitutes close to 38 molecules. Out of which approximately 28 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 9, 2, 14 and 1 respectively. Similarly, the universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 1, 5 and 1 molecules, respectively.

Report covers products from therapy areas Oncology, Women's Health and Infectious Disease which include indications Human Papillomavirus (HPV) Associated Cancer, Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN), Head And Neck Cancer Squamous Cell Carcinoma, Head And Neck Cancer, Anal Cancer, Oropharyngeal Cancer, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Human Papillomavirus Infections, Lung Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Non-Small Cell Lung Carcinoma, Penile Cancer, Rectal Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Vaginal Cancer and Vulvar Cancer.

The latest report Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2018, outlays comprehensive information on the Human Papillomavirus Protein E7 (E7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Human Papillomavirus Protein E7 (E7) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Protein E7 (E7)
  • The report reviews Human Papillomavirus Protein E7 (E7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Human Papillomavirus Protein E7 (E7) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Human Papillomavirus Protein E7 (E7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Human Papillomavirus Protein E7 (E7) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Human Papillomavirus Protein E7 (E7)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Human Papillomavirus Protein E7 (E7) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Human Papillomavirus Protein E7 (E7) - Overview
Human Papillomavirus Protein E7 (E7) - Therapeutics Development
Human Papillomavirus Protein E7 (E7) - Therapeutics Assessment
Human Papillomavirus Protein E7 (E7) - Companies Involved in Therapeutics Development
Human Papillomavirus Protein E7 (E7) - Drug Profiles
Human Papillomavirus Protein E7 (E7) - Dormant Products
Human Papillomavirus Protein E7 (E7) - Discontinued Products
Human Papillomavirus Protein E7 (E7) - Product Development Milestones
Appendix
List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1)
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Products under Development by Companies, H2 2018 (Contd..3), H2 2018
Products under Development by Companies, H2 2018 (Contd..4), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Abion Inc, H2 2018
Pipeline by Advaxis Inc, H2 2018
Pipeline by Bioleaders Corp, H2 2018
Pipeline by BioNTech AG, H2 2018
Pipeline by Cancer Research Technology Ltd, H2 2018
Pipeline by Etubics Corp, H2 2018
Pipeline by Genexine Inc, H2 2018
Pipeline by Hookipa Biotech AG, H2 2018
Pipeline by iBio Inc, H2 2018
Pipeline by IMV Inc, H2 2018
Pipeline by Inovio Pharmaceuticals Inc, H2 2018
Pipeline by MedImmune LLC, H2 2018
Pipeline by Oxford Vacmedix UK Ltd, H2 2018
Pipeline by Selecta Biosciences Inc, H2 2018
Pipeline by Touchlight Genetics Ltd, H2 2018
Pipeline by Transgene SA, H2 2018
Pipeline by VLP The Vaccines Company SL, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Discontinued Products, H2 2018
List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report